Drug Trial Radar · NCT06455319
Precision Administration of Anti-thymocyte Globulin With or Without Verapamil
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 12, 2025
Primary completion
Nov 2028
Study completion Aug 2030
Sponsor
- Lead sponsor
- University of FloridaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Colorado, Denver; University of Miami
- First posted
- Jun 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
T cell directed therapy, anti-thymocyte globulin (ATG), in low doses, has been shown to lower HbA1c and preserve endogenous insulin production (measured by C-peptide) in individuals with recently diagnosed type 1 diabetes (T1D). However, not all individuals who received ATG responded to the therapy (i.e., non-responders). Additionally, use of ATG alone does not address inherent beta cell stress. A calcium channel blocker, verapamil, has demonstrated C-peptide preservation in newly diagnosed T1D. Investigators will identify those mostly likely to respond to ATG using an ex vivo predictive biomarker of response to ATG. In addition, Investigators will use sequential therapies to increase efficacy (ATG followed by verapamil) and explore synergistic mechanisms. This will be assessing with in depth immunophenotyping and quantify biomarkers of beta cell stress, cell death, and abnormal prohormone processing. Finally, novel clinical trial endpoints will be assessed for their ability to predict treatment efficacy earlier than the standard endpoint at 1 year.
Conditions
- Type 1 Diabetes
Interventions
Anti-thymocyte globulin (ATG)Drug
ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).
verapamil extended release capsuleDrug
Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC C-peptide between ATG responder and non-responder armsTime frame: 12 Months
- Change in 2-hr MMTT AUC C-peptideTime frame: 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Barbara Davis Center for Diabetes
Aurora, Colorado · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.